ABSTRACT
INTRODUCTION
Tumor-induced T cell tolerance is well established in patients with cancer and also in murine tumor models [1] . Increasing evidence suggests that one of the main mechanisms responsible for T cell tolerance towards tumors is the microenvironment-mediated conversion of myeloid cells into potent immunosuppressive cells, known as myeloid derived suppressor cells (MDSCs) [2] . These cells have been recently shown to play a role not only in tumor tolerance -by impairing T cell responses -but also in tumor progression and metastasis [3] . Although authors in the field have defined human MDSCs as immature myeloid lineage-negative (LIN -), HLA-DR -and CD11b + or CD33 + cells, with an additional division into CD14 low monocytic (M-MDSCs) and CD15 + granulocytic (G-MDSCs) subsets [3] , several types of immunosuppressive myeloid cells characterized by heterogeneous maturation levels and phenotypes, have been documented over the past years in patients with tumors of different origin [4] .
Human G-MDSCs, are thought to correspond to low-density, immature [5] and mature [6] [7] [8] [9] granulocytes, recovered from the mononuclear cell fraction after density gradient centrifugation of peripheral blood and displaying immunosuppressive activities. Interestingly, even normaldensity neutrophils (NDNs), conventionally isolated from the polymorphonuclear cell fraction of peripheral blood, have been found to be T cell suppressive in certain tumors [10] [11] [12] [13] . Nonetheless, it is still unclear whether G-MDSCs originate from an altered granulopoiesis or they represent specialized neutrophil subsets [14] [15] [16] [17] . In this context, it has been recently proposed to define G-MDSCs based on the lack of HLA-DR antigen, the dim CD33 staining and the expression of CD66b, with CD11b and CD16 being used to differentiate between immature (CD11b -and/or CD16 -) and mature (CD11b + CD16 + ) subsets [16] .
While several types of G-MDSCs have been identified in solid tumors [4] , G-MDSCs have been poorly investigated in hematological malignancies. To date, G-MDSCs defined as CD11b 
CD15
+ [19] , and CD11b 
CD14
-G-MDSCs have been isolated from the peripheral blood mononuclear cell fraction [21] and whole peripheral blood [22] of chronic myeloid leukemia patients. Finally, CD11b + G-MDSCs have been recently identified in cryopreserved peripheral blood mononuclear cells (PBMCs) from patients with chronic lymphocytic leukemia [24] .
Given the scarce information on the existence of G-MDSCs in lymphomas and on the immunodeficiency status often accompanying such malignancies, herein we examined whether the peripheral blood of patients affected by HL or non-Hodgkin lymphoma (NHL) contains granulocytic-lineage myeloid cells exerting suppressive activities toward T cells. In particular, the aims of our study were: i) to investigate whether PBMCs from patients affected by HL 
RESULTS
The percentage of CD66b
HLA-DR -cells is increased in PBMCs from lymphoma patients as compared to healthy donors
PBMCs of both healthy donors and lymphoma patients at diagnosis were analyzed according to the gating strategies reported in Figure 1 and Supplementary Figure 1 , in order to establish whether they could contain candidate G-MDSCs. In brief, within total CD45 + PBMCs we gated on CD66b Figure 1) . Eosinophils were then excluded from the analysis based on their bright CD45 expression [25] (Figure 1 ).
The percentages of CD66b
HLA-DR -cells within PBMCs from healthy donors (n = 48) and the whole cohort of lymphoma patients (n = 124) were then compared ( Figure 2 ). According to our analysis, despite the strong variability from patients to patients (second and third panel rows of Figure 1 , and Figure 2) [16] . Notably, given that the gating strategies used allowed excluding eosinophils from our analysis (Figure 1) anti-CD3/CD28 antibodies, were reduced in these patients as compared to healthy donors ( Figure 4B, 4C ). In addition, an elevated arginase activity was detected in serum samples simultaneously obtained from the same patients ( Figure 4D ). Importantly, CD66b + cell depletion from lymphoma patient PBMCs significantly enhanced T cell proliferation ( Figure 4C ). By contrast, CD66b + cell depletion from PBMCs of patients containing a low percentage of the latter cells (< 5% (Supplementary Figure 4) 
DISCUSSION
Novel areas of research for lymphoma patients include improving the efficacy of adoptive cellular therapies, modulating T regulatory cells, developing novel lymphoma vaccine and enhancing tumor-specific innate immune response [27] . In the latter context, this study reports that an expanded population of immunosuppressive CD66b By contrast, mature CD14 + HLA-DR (low)/− monocytes with tested immunosuppressive activity (M-MDSCs) were previously reported in the peripheral blood of 40 patients with aggressive and indolent B-cell NHL [28] , therefore allowing to hypothesize the presence of both G-MDSCs and M-MDSCs in such a context, as already observed in solid tumors [4, 29] .
We found that CD66b + cells as activated LDNs, given their higher expression of CD11b and CD66b as compared to autologous and healthy donor-derived NDNs. Interestingly, populations of mature activated granulocytes, endorsed with G-MDSCs characteristics, were previously described in the mononuclear cell fraction of peripheral blood samples from solid tumor patients [6, 9] . According to the aforementioned studies, a status of activation was responsible for the phenotypic and functional changes -consistent with those of G-MDSCs -observed in these populations of lowdensity granulocytes, which were shown to inhibit T cells via H 2 O 2 production [8] or arginase release from their intracellular granules [6] [7] 9] . In agreement with the latter observations, we also found an elevated arginase activity in sera obtained from a representative sample of HL and B-cell NHL patients, suggesting that activated neutrophil subsets (i.e. LDNs) could exert an arginase-mediated immunosuppressive activity even under lymphoma settings. Obviously, the prevalence of CD11b [15] , their kinship [17] with conventionally defined G-MDSCs (e.g., immature myeloid cells expressing granulocytic markers) [3] , and finally the need for a definite consensus about their classification as G-MDSCs or specialized/activated neutrophils.
In our study, independently from the lymphoma type (i.e. HL or NHL), we observed a lack of association between the percentage of CD66b 
HLA-DR
− cells was associated with unfavorable prognostic scores and, mostly, with a significantly worse FFDP, therefore suggesting that at least in lymphomas, the generation of G-MDSCs is more related to the biological aggressiveness of the disease than to its size. Accordingly, among aggressive B-cell NHL patients, those affected by a particularly unfavorable type of diffuse large B-cell lymphoma (DLBCL) (i.e. "double" and "triple expressor" DLBCLs, n = 7) [30] 
− G-MDSCs at the time of diagnosis and disease prognostic scores and outcome, suggests that the latter cells may be a suitable prognostic marker in HL and B-cell NHL. In contrast to our observation, the only report analyzing G-MDSCs in lymphomas found, in a cohort of 60 HL patients, a prognostic significance for immature CD34 + MDSCs but not for G-MDSC [23] . However, it should be noted that the latter G-MDSCs were identified by whole blood flow cytometry as CD11b + cells were found to be mostly composed of activated LDNs. Moreover, in the same patients, the expansion of the latter cells was associated with a significantly decreased percentage of the subpopulations at the intermediate and immature stages of maturation, thus suggesting their rapid lymphoma-mediated recruitment to a mature and activated status.
Overall, our results demonstrate that in HL and B-cell NHL patients a population of functionally defined G-MDSCs mainly composed of mature activated LDNs is present. Besides identifying a possible prognostic marker, these findings disclose a previously unknown G-MDSCmediated mechanism of immune-escape in lymphomas, therefore anticipating future targets for therapeutic interventions. Further studies are awaited in order to establish whether CD66b 
MATERIALS AND METHODS

Patients and healthy donors
Between February 2010 and December 2014, 124 patients referred to our Institution for a new diagnosis of lymphoma, (31 HL, 93 B-cell NHL), were prospectively enrolled to this study upon informed consent. The study received approval from the Ethics Board of the Azienda Ospedaliera Universitaria Integrata di Verona (Project 2371). Criteria of inclusion were: a new diagnosis of HL or B-cell NHL, and age ≥ 16 years. Criteria of exclusion were: the presence of infections, rheumatological disorders, malignancies other than lymphoma, concurrent or previous steroid treatment, and ongoing chemotherapy. Patient characteristics are reported in Table 1 . Forty-eight sex-and age-matched healthy volunteer donors were also enrolled at the Blood Bank of our Institution at the time of blood donation, upon informed consent.
Histological diagnoses were done according to WHO criteria [32] . Based on a clinically-oriented classification [33] , the 93 B-cell NHL cases were subsequently divided in the indolent [n = 31] and aggressive [n = 62] subgroups and analyzed accordingly. Among aggressive B-cell NHLs, diffuse large B cell lymphomas (DLBCL) were immunohistochemically defined "double expressors" and "triple expressors" based on their expression of MYC and BCL-2 or BCL-6, and MYC, BCL-2 and BCL-6, respectively [30] .
Patients underwent complete blood count and blood chemistry measurements. Clinical staging included physical examination, computed tomography scans of chest, abdomen, pelvis and brain, positron emission tomography, and bone-marrow biopsy. Patients were staged according to the Ann Arbor staging system [34] . The term "bulky" was referred to lymphomas in the chest that were at least onethird as wide as the chest, or lymphoma in other areas that were at least 10 centimeters across.
At diagnosis, the Hasenclever Prognostic Index [35] was calculated for patients affected by HL, while the Follicular Lymphoma International Prognostic Score (FLIPI) [36] and the International Prognostic Score (IPI) [37] were calculated for indolent and aggressive B-cell NHL patients, respectively. Both patients affected by HL and B-cell NHL, were treated according to the European Society Medical Oncology (ESMO) guidelines [38] . Patients who underwent, an intensive high-dose sequential chemotherapy with stem cell autografting [39] as upfront treatment (i.e. patients affected by mantle cell lymphoma) were excluded from the study.
Peripheral blood samples from patients at the time of diagnosis or healthy donors were freshly obtained by venipuncture in EDTA-treated sterile tubes. After at least 3 months since the completion of first-line chemotherapy (and/or radiotherapy whenever delivered) and in case of complete remission achievement, patients were required to undergo a further venipuncture for peripheral blood sample collection.
Serum samples from patients at the time of diagnosis or age-and sex-matched healthy donors were obtained after collection of peripheral blood by venipuncture in gel and clot activator tubes, promptly centrifuged at 1800 g for 10 minutes, and stored at −80°C until used.
G-MDSCs identification by flow cytometry
For both patients and healthy donors, granulocytes and PBMCs were freshly obtained from 3 ml of whole blood, collected in EDTA and rigorously processed within 2 hours over centrifugation on Ficoll-Paque solution (GE Healthcare Life Sciences, Cleveland, Ohio), according to manufacturer's protocol. G-MDSCs were identified in PBMCs based on the lack of HLA-DR, the dim CD33 staining, and the expression of CD66b, with CD11b and CD16 being used to differentiate between immature (CD11b − and CD16 
Morphology
To assess cell morphology, cytospins of PBMCs from patients at diagnosis or healthy donors were obtained by centrifuging 5 × 10 4 cells on microscope slides and stained by the Giemsa/May-Grunwald procedure. Pictures were taken using a Leica DFC 30FX Digital Color Camera on a Leica DM 6000 B microscope at a 40× magnification and processed with Adobe Photoshop (Adobe Systems).
MDSCs depletion and T cell proliferation assay
Depletion of MDSCs from freshly isolated PBMCs of patients at diagnosis or healthy donors were performed by labeling PBMCs with anti-CD66b-FITC followed by anti-FITC magnetic bead separation, according to the specifications of the manufacturer (Miltenyi Biotech). The percentage of CD66b + cells in the negative selected population was < 1 %.
To measure T cell proliferation, PBMCs (depleted or not of CD66b + cells) freshly isolated from patients at the time of diagnosis or healthy donors were labeled with carboxy-fluorescein diacetate succinimidyl ester (CFSE) (CellTrace™ CFSE Cell Proliferation Kit, Life Technologies) according to manufacturer's instructions. 
III-IV 35
Bulky disease 25
Bone-Marrow involvement 9
Spleen involvement 17
Extranodal involvement 30
Systemic symptoms 15
Total patients 124
Median age (range) 64 years Male/Female 82/42 *Hodgkin lymphoma: classic type (n = 25), lymphocyte predominant (n = 6). ** non Hodgkin lymphoma indolent: follicular grade 1-3a (n = 12), marginal zone (n = 17), and mucose-associated lymphoid tissue lymphoma (n = 2); ** non Hodgkin lymphoma aggressive: follicular grade 3b (n = 8), diffuse large B cell (DLBCL) (n = 54, including: 1 MYC and BCL-2 and 3 MYC and BCL-6 double expressors, and 3 MYC, BCL-2 and BCL-6 triple expressors).
CFSE-labeled PBMCs were stimulated with mAbs anti-CD3 (30 ng/ml) and anti-CD28 (100 ng/ml) ( 
Arginase activity
Thawed serum samples (100 µl) were loaded on Amicon ® Ultra-0.5 Centrifugal Filter Devices (MerckMillipore, Darmstadt, Germany), diluted to 500 µl with H 2 O and centrifuged at 14,000 g for 30 min to remove urea. Concentrated samples were diluted with H 2 O and tested for arginase activity as previously described (40, 41) . Arginase activity (Units per Liter of sample, U/L) was defined as the amount of enzyme able to convert 1 µmole of L-arginine to ornithine and urea per minute at pH 9.5 and 37°C.
Statistics
To perform the association analyses, values not showing a normal distribution were log transformed and the Shapiro-Wilk test was used to test their normality. Differences of quantitative normally distributed variables between 2 or more groups were tested by Student's t-test or one-way ANOVA, respectively. When variables resulted to be not normally distributed, even after log transformation, non-parametric rank-based tests were used on untransformed values. In particular for unpaired data, Mann-Whitney and Kruskal-Wallis tests were used to compare 2 or more than 2 groups respectively. Nonparametric Freidman test used when comparing paired data.
Associations between quantitative variables were assessed using regression linear models. Covariates were included into the models when relevant.
The percentage of CD11b Freedom from disease progression (FFDP) was defined as the interval from the initiation of the primary treatment to the first recurrence of disease (progression or relapse) [35] . Response criteria were established according to Cheson et al. [42] . Patients in complete remission were censored on June 30th 2015. Overall 117/124 (94.3%) patients were evaluable for disease outcome at that time. Among the 7 patients not evaluable for clinical outcome, 1 with aggressive B-cell NHL was lost to follow-up, 1 with aggressive B-cell NHL refused chemotherapy due to the old age, and 5 with indolent B-cell NHL were not considered for analysis because they were lost to follow-up (n = 2) or because they did not require any treatment (n = 3). Survival distributions of two samples were compared using the logrank Mantel-Cox test. Statistical analyses were performed using the R package version 3.2.0 [43] and GraphPad Prism 5.0 software (GraphPad Software, Inc, California).
